Description

Genorise Recombinant Human PAPP-A Protein Summary

Alternative names for PAPP-A: Pappalysin-1, pregnancy-associated plasma protein A, PAPPA

Product Specifications

Background: 

Pappalysin-1, also known as pregnancy-associated plasma protein A, is a protein encoded by the PAPPA gene in humans.[1,2] PAPPA is a secreted protease whose main substrate is insulin-like growth factor binding proteins (IGFBPs).[3] Pappalysin-1 is also used in screening tests for Down syndrome.[4] PAPPA’s proteolytic function is activated upon collagen binding. It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses. For example, low PAPPA may be commonly seen in prenatal screening for Down syndrome.^[4] Low levels may alternatively predict issues with the placenta, resulting in adverse complications such as intrauterine growth restriction, preeclampsia, placental abruption, premature birth, or fetal death. PAPP-A has been shown to interact with major basic protein^[2][4] and specifically inhibits the third component of human complement (C3).[6] PAPP-A interacts with serine proteinases.[7] In STEMI patients, Stanniocalcin-2 and IGFBP-4 emerged as independent predictors of all-cause death and readmission due to HF. The Stanniocalcin-2/PAPP-A/IGFBP-4 axis exhibits a significant role in STEMI risk stratification.[8]

References

1. Kristensen T, et al. (1994). Biochemistry. 33 (6): 1592–8.
2. Overgaard MT, et al. (2000) J. Biol. Chem. 275 (40): 31128–33.
3. Durham SK, et al. (1994). J. Bone Miner. Res. 9 (1): 111–7.
4. Breathnach FM, Malone FD (2007). Curr. Opin. Obstet. Gynecol. 19 (2): 176–82.
5. Overgaard MT, et al. (2003) J. Biol. Chem. 278 (4): 2106–17.
6. Bischof P, et al. (1984). Placenta. 5 (1): 1–7.
7. Zorin NA, et al. (1995). Clin. Chim. Acta. 239 (1): 47–55.
8. Cediel G, et al. (2018) Cardiovasc Diabetol 17 (1), 63

Product Citations